



AF/1425
15

CASE 4-30028/A/PCT

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Joseph J. Borovian
Type or print name

Joseph J. Borovian
Signature

May 3, 2001
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

Art Unit: 1625

PORTMANN ET AL.

Examiner: P. Morris

INTERNATIONAL APPLICATION NO: PCT/EP 98/03427

FILED: 8 JUNE 1998

U.S. APPLICATION NO: 09/125,329

35 USC §371 DATE: 8 SEPTEMBER 1998

FOR: CRYSTAL MODIFICATION OF 1-(2,6-DIFLUOROBENZYL)-1H-
1,2,3-TRIAZOLE-4-CARBOXAMIDE AND ITS USE AS
ANTIEPILEPTIC

Assistant Commissioner for Patents
Washington, D.C. 20231

COMMUNICATION

Sir:

It has just been noted that in the discussion of the "obviousness-type double patenting" rejection on Page 10 of the Appeal Brief filed April 18, 2001, the "copending" application is referred to as U.S. Application No. 09/599,699 when, in fact, it is U.S. Application No. 09/599,688. This inadvertent error is regretted.

Respectfully submitted,

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027

Joseph J. Borovian
Joseph J. Borovian
Agent for Applicants
Reg. No. 26,631
(908) 522-6921

JJB/pk
Attach.: Postcard
Date: May 3, 2001